Overview of AKR1C3: Inhibitor Achievements and Disease Insights
Yang Liu(Tianma Microelectronics (China)), Haopeng Sun(China Pharmaceutical University), Yijun Liu(Guangdong University of Technology), Ying Chen(Sun Yat-sen University), Li Zhao(Jilin University), Feng Feng(Nanjing Medical University), Wenyuan Liu(China Pharmaceutical University), Siyu He(Tongji University), Qinglong Guo(Nanjing Tech University)
Cited by 92
Related Papers
Degradation of proteins by PROTACs and other strategies
|Acta Pharmaceutica Sinica B|2019|312
Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease
|European Journal of Medicinal Chemistry|2017|307
MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II
|Human Molecular Genetics|2007|289
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
|Journal of Medicinal Chemistry|2019|270
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
|European Journal of Medicinal Chemistry|2018|200